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Abstract: The possibilities and implementation of wearable cardiac monitoring beyond atrial fib-
rillation are increasing continuously. This review focuses on the real-world use and evolution of
these devices for other arrhythmias, cardiovascular diseases and some of their risk factors beyond
atrial fibrillation. The management of nonatrial fibrillation arrhythmias represents a broad field of
wearable technologies in cardiology using Holter, event recorder, electrocardiogram (ECG) patches,
wristbands and textiles. Implementation in other patient cohorts, such as ST-elevation myocardial
infarction (STEMI), heart failure or sleep apnea, is feasible and expanding. In addition to appropriate
accuracy, clinical studies must address the validation of clinical pathways including the appropriate
device and clinical decisions resulting from the surrogate assessed.
Keywords: wearables; remote monitoring; cardiac monitoring; artificial intelligence; arrhythmia;
heart failure; digital health; mobile health
1. Introduction
Advances in wearable technologies have provided new opportunities for the diagnosis
and management of cardiovascular diseases and their risk factors. Technologies that are
commonplace in clinical situations, such as monitors of heart rate and rhythm and blood
pressure, are now available directly to consumers.
Traditionally, when a wearable medical device was advocated by a healthcare provider
and prescribed, their use was supported by evidence of effectiveness, reliability and safety.
Ongoing scrutiny of these devices was, through the clinical lens of treatments and outcomes,
prompted by device diagnostics as well as through the regulatory processes that reviewed
these measures and the potential additive value for reimbursement.
Initially, medical devices that are marketed directly to consumers were largely for
health and wellness tracking and fitness assessment. However, these devices and their
biologic sensors have become increasingly more complex, and as a consequence, their
potential utility to diagnose and prompt treatment for cardiovascular disease and its risk
factors has increased. If a device is used to support a healthy lifestyle and monitor fitness
or activity levels, it may not require the same regulatory review as a wearable medical
device that is prescribed by a healthcare provider. However, if the data provided can be
used to influence therapeutic decisions and medical decision making, then the regulatory
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environment can be much more extensive, and claims for use must be supported with data
of safety, efficacy and value.
In the United States, the regulatory organization that oversees claims of efficacy and
safety is the Food and Drug Administration (FDA). In the United Kingdom, this is the
Medicines and Healthcare Products Regulatory Agency (MHRA); in the European Union,
it is the European Medicines Agency (EMA). The FDA has published multiple guidelines
(https://www.fda.gov/medical-devices/digital-health-center-excellence (accessed on 2
April 2021)) for products in which regulatory requirements will be enforced as well as for
others deemed “low risk” in which they will not. In the United Kingdom, the National In-
stitute for Health and Care Excellence (NICE) published a standards framework for digital
technologies, which provides the requirements and metrics new technologies must meet
in order for approval (https://www.nice.org.uk/about/what-we-do/our-programmes/
evidence-standards-framework-for-digital-health-technologies (accessed on 2 April 2021)).
This market of direct-to-consumer healthcare is increasing substantially. In the United
States, it already represents a USD 700 billion industry [1]. A direct-to-consumer approach
remains attractive to industry as a means to reach a broad consumer base with fewer
regulatory hurdles. The wearable industry will expand further with the rapid use and
assimilation of digital health. As these devices are increasingly being offered and utilized,
it has been difficult for healthcare providers to manage the data and recommend which, if
any, tools should be used for the diagnosis and management of cardiovascular diseases
and its risk factors.
Healthcare providers play a critical role in helping patients navigate their health
and must adapt to these technologies. However, this role is dependent on some degree
of understanding about the validity of these medical devices and their associated value
and limitations. For example, for cardiac rhythm monitoring, patients often assume that
the monitoring is continuous, as it appears this way in the displayed graphs or figures
on their smartphone. Nonetheless, current direct-to-consumer cardiac monitors are not
continuous and are for the surveillance or “spot checking” of arrhythmias and, at this time,
do not replace the continuous monitors that are prescribed by a healthcare provider. Those
devices that require patient activation will remain limited due to their under-detection of
subclinical or minimally symptomatic arrhythmias. Additionally, the amount and quality
of data recorded and stored with direct-to-consumer cardiac devices depend on the battery
capacity, storage capabilities, size of the device and cost of the device.
Early use of direct-to-consumer cardiac wearables beyond fitness has been led by those
devices that diagnose cardiac arrhythmias, in particular, atrial fibrillation (AF). This review
will focus on the real-world use and evolution of these devices for other arrhythmias, other
cardiovascular diseases and some of their risk factors beyond AF.
2. Non-AF Arrhythmia Detection
The conventional 12-lead electrocardiogram (ECG) provides an accurate assessment
of cardiac arrhythmias. Nonetheless, it offers only a “snapshot” of electrical signals and
misses arrhythmias that occur outside this period. Hence, continuous ECG monitoring
systems have been developed to compensate for this limitation. Currently, Holter monitors
are the mainstay device for the ambulatory detection of clinical arrhythmias. Nonetheless,
these devices are impractical in terms of size and offer only a limited duration of continuous
monitoring. For a longer duration of cardiac monitoring (≤30 days), external loop and
event monitors (intermittent) are available. An alternative is an implantable loop recorder,
which may last for up to three years, but this involves an invasive procedure with potential
risks, albeit small. Overall, there are significant cost implications associated with these
established devices, in terms of hardware, software and technician support. As a result,
these traditional systems are not directly accessible by the general population.
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2.1. Types of Cardiac Monitoring
Over the past decade, there has been a surge in new wearables (e.g., patches and
wristbands) that are capable of monitoring heart rate and ECG signals. The application
of machine learning and artificial intelligence (AI) has further enhanced the role of these
devices. Each offers a convenient, relatively affordable and directly accessible method
of cardiac monitoring to the general public. Alongside an increase in consumers who
are health-conscious or curious, these devices have been embraced with much enthu-
siasm. Table 1 summarizes different types of cardiac monitoring [2]. Advantages and
disadvantages of wearables for arrhythmia monitoring are shown in Figure 1.









12-lead ECG Single timepoint No No Easy and cheap method of monitoring; gooddiagnostic capability if captures arrhythmia
Holter
monitoring 72 h Yes Yes Short-term but quantifies burden of arrhythmia
Patch monitor 1–3 weeks Yes Yes Intermediate duration with straightforwardapplication and improved patient compliance
External loop
recorder 1 month No Yes
Provides long-term monitoring of rare,
sustained events
Smartphone
monitor Indefinite No Yes
Available direct to consumer; inexpensive; provides
long-term monitoring of rare, sustained events;
requires a Smartphone
Mobile cardiac
telemetry 1 month Yes Yes
Real-time cardiac monitoring with remote
capability; relatively expensive
Implantable loop
recorder 3 years Yes Yes
Provides long-term monitoring of arrhythmias;
requires invasive procedure; relatively expensive
Pacemaker or ICD Indefinite (with boxchanges) Yes Yes
Long-term monitoring with remote capability; able
to deliver therapy in certain situations; requires
invasive procedure; expensive
WCD Indefinite Yes Yes
Very expensive; able to deliver therapy for





Indefinite Yes Potentially Rapidly developing field that is yet tobe established
ECG, electrocardiogram; ICD, implantable cardioverter-defibrillator; WCD, wearable cardioverter-defibrillator.
2.2. Mobile Cardiac Outpatient Telemetry
The advantages of these new wearables for the detection of cardiac arrhythmias have
primarily been investigated in the context of AF, and stem largely from their longer du-
ration of monitoring (i.e., detection of subclinical events). In the past, the use of a mobile
cardiac outpatient telemetry (MCOT) system has been shown to provide a higher diag-
nostic yield than standard patient-activated external loop recorders (88% vs. 75%) among
patients with symptoms suggestive of significant cardiac arrhythmia and a nondiagnostic
result from 24-h Holter [3]. The MCOT system had a particular role in the detection of
asymptomatic clinically significant arrhythmias [4], highlighting the benefits of continu-
ous cardiac monitoring in at-risk patients. Newer MCOT systems, such as the NUVANT
Mobile Cardiac Telemetry (Corventis, San Jose, CA, USA), comprise a wireless-enabled
arrhythmia monitor that utilizes a low-profile PiiX sensor, lasting up to seven and a half
days, to collect real-time ECG data. This device has shown promise in several settings [5,6]
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and been previously found to be associated with good compliance [7]. The use of these
wireless-capable wearable devices enables remote physician monitoring and immediate
action in the event of a serious cardiac arrhythmia, similar in many ways to modern day
implantable pacemakers and defibrillators.
Figure 1. Generic advantages and disadvantages of wearables for monitoring of cardiac arrhythmia.
2.3. Ultraportable Electrocardiogram Patches
Another form of wearables that has gained popularity for the detection of arrhythmias
is ultraportable ECG patches. An example is the Zio Patch (iRhythm Technologies, San
Francisco, CA, USA) that provides a continuous single-lead ECG signal for up to 14 days
without the need for battery replacement during this time. The device may also be activated
during symptomatic episodes. The advantage of this device over traditional Holter systems
is that it can be mailed directly to patients and self-applied. Once the monitoring period is
over, it can be mailed back for analysis. It has recently been utilized to detect nonsustained
ventricular tachycardia and premature ventricular contractions in a population-based
research setting [8]. In a study of 146 patients, Barrett et al. demonstrated that the Zio
Patch had a higher diagnostic yield for total arrhythmia detection (atrioventricular block,
pause, supraventricular tachycardia, ventricular tachycardia and polymorphic ventricular
tachycardia [and AF]) compared to Holter monitoring [9]. However, these results were
largely driven by an imbalance in the monitoring duration (24 h with Holter vs. 14 days
with Zio Patch). In fact, a secondary analysis of device performance over a simultaneous
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24-h period found that the Holter monitor detected significantly more arrhythmic events
compared to the Zio Patch. Nonetheless, 93.7% of patients in the study found the patch to be
comfortable as opposed to 51.7% for the Holter monitor [9]. A cross-sectional study of 26,751
consecutive patients receiving the Zio Patch for clinical indications of cardiac monitoring
demonstrated high patient compliance with a significant proportion of patients who had
arrhythmias suffering from these events after the initial 48 h [10], thereby reinforcing the
need for longer term monitoring with patient-tolerable devices.
Among patients presenting to the emergency department with symptoms suggestive
of cardiac arrhythmia, but deemed suitable for outpatient ambulatory cardiac monitoring,
application of the Zio Patch for up to 14 days was associated with a diagnostic yield of
63.2% for significant arrhythmias [11]. Similar application in patients with unexplained
syncope who presented to the emergency department resulted in a diagnostic yield of
27.9% [12]. Conversely, the use of the Zio XT Patch in a community-based sample of
older individuals led to relatively low detection rates of atrioventricular block (2nd degree
Mobitz II or 3rd degree; 3%) and pauses of more than three seconds (3%) [13]. These
results underscore the importance of patient selection in the overall diagnostic yield of
wearable devices.
Other patch-based ECG monitoring systems have also been described for the detection
of cardiac arrhythmias. For this purpose, the Wellysis S-Patch Cardio has been found
to provide good quality ECG traces that enable an evaluation of supraventricular and
ventricular arrhythmias [14]. Separately, the ATP100 patch has also been found to have
comparable results to conventional ECG monitoring systems [15].
2.4. Delivery of Therapy with Wearables
Additional to the detection of cardiac arrhythmias, wearables may also have a role in
delivering therapy. In this regard, wearable cardioverter-defibrillators (WCD) are designed
to deliver shocks for potentially life-threatening ventricular arrhythmias. In the VEST trial,
the use of the WCD (LifeVest, Zoll, Pittsburgh, PA, USA) in patients with acute myocardial
infarction (MI) and severely impaired left ventricular function (ejection fraction ≤ 35%) led
to 20 appropriate and 9 inappropriate shocks [16]. Despite this, there was no significant
difference in the rate of arrhythmic death in the device group compared to the control
group. The authors reported that the lack of survival benefit with the WCD may have been
due to the low adherence to wearing the device. In real-world studies of the WCD, the
rate of appropriate shock is 1.1–1.3% with an incidence of inappropriate shock of less than
1% [17–19]. Moreover, in some situations, the use of the device facilitated long-term care
decisions regarding the need for implantable cardioverter-defibrillator (ICD) implantation.
2.5. Important Considerations
More recently, other forms of wearables with ECG monitoring capabilities have been
designed. An example is the smart textile-based garments that have the ability to measure
ECG from multiple locations [20–22]. These novel technologies may further expand this
already rapidly developing field.
Although there are many clear advantages of longer ECG monitoring afforded by
these direct-to-consumer wearables, there are some limitations worth considering. First, the
quality of ECG traces is likely to be significantly reduced in the absence of medical supervi-
sion. Second, the application of these devices will invariably generate a significant amount
of ECG traces that require interpretation. In many situations, automated algorithms with
excellent accuracy in classifying single-lead ECG from wearables compared to standard
12-lead ECG [23] have been designed. However, there remains an issue with unclassified
traces in as many as 33% of ECGs due to baseline artefact [24,25]. This may be reduced, to
a degree, by the manual interpretation of the traces, but this also means a greater workload
for healthcare professionals [24]. In the future, improvements in adaptive filters may
help address this issue. Third, although these wearables may have a use for the initial
detection of cardiac arrhythmias, it is important to note that they have a restricted role
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for the characterization of such events, particularly those relating to tachycardia. Fourth,
the ECG traces acquired from these wearables do not correspond directly to those from
conventional 12-lead ECG and Holter monitoring systems.
Additional to direct ECG monitoring systems, as described above, there have been
efforts to correlate ECG traces with photoplethysmography (PPG) waveforms that rely
on light transmission from smartphones to skin capillaries for the better detection of
arrhythmias. Examples are shown in Figure 2.
Figure 2. Examples of photoplethysmography (PPG) recordings for ventricular bigeminy and atrial flutter. The top graph
shows PPG signals of a 60-s recording. The bottom-left tachogram displays all consecutive pulse signal intervals. For
ventricular bigeminy, it can be seen that there are heart beats with alternating intervals. For atrial flutter, the heart rate is
rapid with an average of 146 bpm. The Lorenz plot provides a visual representation for clustering patterns.
For this purpose, each peak on the PPG signal is translated into an R wave which
is then analyzed using prespecified algorithms. In the past, the Tateno-Glass method
was described to test for the variation in R-R intervals [26,27]. Nevertheless, this method
relied on the use of training data, which are often not representative of specific cohorts.
Hence, newer algorithms that overcome this limitation may be preferred. More recently,
Dash et al. described an algorithm that combines three statistical techniques: Root Mean
Square of Successive R-R Differences (quantify variability), Turning Points Ratio (test for
randomness of the time series) and Shannon entropy (characterize complexity) [28]. Other
algorithms include the support vector machine, artificial neural network and k-nearest
neighbor [29–31].
However, most of these algorithms were based on explicit features of peak-to-peak
intervals with loss of information, such as amplitudes or waveforms, which decreases
their accuracy in the presence of a high burden of premature atrial complexes (PACs).
In this regard, deep learning-based algorithms that utilize all training data may perform
better, as they are able to analyze characteristics such as amplitude, frequency and wave
morphology [29].
Though most studies on PPG performance have focused on the detection of AF, it
may also have a role in screening for other arrhythmias. In a small study of 20 participants
comparing the use of a wrist wearable (Philips Cardio and Motion Monitoring Module)
equipped with integrated optical PPG and accelerometer sensors against a 12-lead Holter,
the former was able to identify episodes of bradycardia and tachycardia with a sensitivity
of 85.0% and 99.4%, and specificity of 89.1% and 99.1%, respectively [32]. Elsewhere,
Corino et al. used the Empatica E4 wristband and developed a classifier machine learning
software that correctly identified arrhythmias, including atrial flutter, atrial tachycardia
and premature ventricular contractions, with a sensitivity, specificity and accuracy of 75.8%,
76.8% and 80%, respectively. Furthermore, it was able to discriminate these arrhythmias
from AF with a false negative rate of about 25% [33].
These PPG-based systems represent a potentially exciting avenue for more convenient
ECG monitoring. Contactless rhythm analysis of facial PPG signals has even been described,
which can be performed for several individuals simultaneously [34,35]. However, there
are several constraints with this system. Overall, the PPG signals are highly vulnerable to
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artefacts that make traces uninterpretable, resulting in discarded data [36]. Furthermore,
darker skin pigmentation and ambulation are factors that have been shown to reduce the
accuracy of PPG-based devices, due to the modulation of the light wavelength by melanin
and decreased device-to-skin contact [23,37]. The interpretability of black-box algorithms
may also present a challenge for physicians who are expected to diagnose the results of
these wearables.
2.6. Heart Rate Variability Analysis and QT Measurement
Other applications of wearables beyond the detection of cardiac arrhythmias are heart
rate variability (HRV) analysis and QTc measurement. Pulse rate variability detected using
PPG has been shown to be highly correlated with HRV measurements and, therefore, may
be an important tool for the assessment of the autonomic nervous system and cardio-
vascular risk profile [38]. In a preliminary study of a wearable armband ECG monitor,
Lazaro et al. found excellent results for HRV analysis using this new device compared
to conventional Holter monitoring [39]. An advantage of this armband monitor over
patch-based devices is that it does not utilize hydrogels, which may cause skin irritation.
The measurement of QTc is an important aspect of risk assessment in specific populations
and particularly in patients who are commencing certain medications with known QT
prolonging effects. In a study of 36 patients (20 long QT syndrome [LQTS]; 16 controls),
Castelletti et al. reported that the use of a remote monitoring ECG system with automated
QTc measurement (BodyGuardian) was able to reliably identify prolonged QT intervals
in comparison to a standard 12-lead Holter monitoring system (Mortara HScribe) [40].
Despite this, 34% of measurements had a disagreement of more than 20 ms, suggesting
that further refinement is needed.
Overall, there are significant implications to contemplate with the use of wearables
for the detection of cardiac arrhythmias (and other cardiovascular indices). Perhaps most
importantly, there is a paucity of robust data comparing the accuracy, clinical implications
and cost of these new wearables to established ECG systems. There may be a role for these
devices as a screening rather than diagnostic tool. However, this approach will likely be
associated with a low positive predictive value, which will invariably lead to increased
levels of anxiety in people and unnecessary downstream testing in an otherwise largely
asymptomatic population. Furthermore, the potential impact on healthcare resources (e.g.,
unwarranted visits to the emergency department) should not be underestimated. Moreover,
the uptake of these wearables is mainly among the younger population who are inherently
less likely to suffer from serious clinical arrhythmias, unlike their older counterparts,
who may derive more benefits but may be reluctant to adopt these new technologies.
Overall, the widespread, unregulated adoption of these new untested wearables for the
detection of arrhythmias in an unselected population is unlikely to be beneficial. Instead,
it may have a role in the long-term screening of clinically significant arrhythmias among
high-risk patients.
3. ST-Segment Elevation Myocardial Infarction
An ST-segment elevation myocardial infarction (STEMI) is an abrupt severe manifes-
tation of coronary artery disease associated with high morbidity and mortality, particularly
if not diagnosed and treated rapidly. Ischemic heart disease is and will remain a significant
contributor to death and disability worldwide [41]. In the United States, 550,000 first
episodes of MI occur each year, and another 200,000 recurrent episodes occur [42]. As early
diagnosis and management remain critical links in the outcomes related to STEMI, the
broad availability and use of wearables and smartphones may help improve outcomes.
The diagnosis of an STEMI is based upon the presence of ST-elevation on a 12-lead
electrocardiogram (ECG). ECG machines are available worldwide, but typically within the
confines of healthcare resources, such as hospitals and clinics. However, when diagnosis
can be made accurately, with the remote assistance of specialized care, appropriate treat-
ment can be directed quickly and favorable outcomes of an early response maintained [43].
Sensors 2021, 21, 2539 8 of 25
The majority of smartphone and smartwatch ECGs provide single lead telemetry and
have been used for arrhythmia detection. A single lead is not ideal for the detection of
arrhythmia, but much worse for ischemic disease in which leads outside of the territory
of injury may show no significant ECG findings. Dynamic use of a smartwatch beyond
the traditional configuration can replicate the Einthoven (leads I, II and III), and pseudo-
unipolar chest leads to replicating a 6-lead ECG [44]. However, the nuances of segmental
samples using a traditional smartwatch to obtain a 6-lead ECG make this approach limited
for the diagnosis of STEMI.
A standard 12-lead ECG requires the use of 9 electrodes that are strategically placed
on the chest and limbs. Recently, a system (AliveCor, Mountainview, CA, USA) that uses
2 electrodes on a smartphone-associated sensor that obtains sequential single-lead ECG
measurements that are averaged, uses a single limb lead as the ground for the precordial
leads and requires vector summation of the multiple tracings was proposed. The system
then creates what has been labelled as an “12-lead equivalent ECG”, as shown in Figure 3.
Figure 3. The figure shows a standard ECG (A) and a compared “12-lead equivalent ECG” (B)
from the same patient using 2 electrodes connected to a smartphone associated sensor as shown
(C) that obtains multiple sequential single-lead ECG measurements that was used in the St. Leuis
trial. A next-generation concept for improved detection from AliveCor (Mountainview, CA, USA)
is shown in (D) for smart phone-based cordless detection of STEMI with direct lead equivalents
annotated. (Figures (A–C) are courtesy of Dr. Brent Muhlestein and Viet Le. Figure (D) is courtesy of
Dr. Dave Alpert).
The accuracy of the smartphone-based 12-lead equivalent ECG was measured against
a standard 12-lead ECG in 200 consenting patients who presented with acute chest pain
in the ST-Leuis trial [45]. The smartphone 12-lead equivalent ECG quality was graded as
good in 151 (74.0%), fair in 32 (15.7%), poor in 8 (3.9%) and uninterpretable in 13 (6.4%) of
the patients. An STEMI or STEMI-equivalent diagnosis (new left bundle branch block, etc)
was identified by a standard 12-lead ECG in 57/204 (27.9%) of the analyzed ECGs. The
sensitivity, specificity and positive and negative predictive values for STEMI and STEMI
using the 12-lead equivalent ECG provided by the smartphone were 0.89, 0.84, 0.70 and
0.95, respectively, when compared to the standard ECG.
Although the results for the ST-Leuis feasibility study were promising, several key
technologic issues were identified and can be used with technological refinements of the
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tool. First, the smartphone technique requires sequential measurements to be made, which
produce tracings that are contemporaneous but nonsimultaneous, and this can introduce
variance into the signal and opportunity for error. Next, augmented limb leads are a
computer averaged summation of multiple tracings; if these tracings have artifact or signal
contamination, then the negative impact to the signal can be magnified. The precordial
leads are obtained using a single limb lead for ground, and a second lead for a group may
improve signal quality and minimize failure risk. Finally, the tracings are presented as an
averaged tracing, so no raw signal data are preserved to allow direct interpretation. To
minimize morphological corruption by signal averaging, algorithms were employed to
exclude arrhythmia, such as premature ventricular complexes from the averaging process;
such exclusion may be problematic with the dynamic variation of morphology that can be
seen with acute ischemia or in a state when frequent ectopy may be present.
In a small case series of 2 patients that presented with an STEMI, an Apple Watch
4 (Apple, Cupertino, CA, USA) was used to create a 3-lead ECG [46] as an alternative
diagnostic method. The 3 leads obtained matched the corresponding 3 leads on a standard
ECG to suggest the potential application of multisite sampling using a smartwatch for the
early detection of myocardial injury.
As these technologies improve from an ease of use and technology perspective, or
others emerge, it is very feasible that the broad early diagnosis of STEMI using smart
devices will materialize. Critical to these advances is the need for healthcare systems to
rapidly assimilate the data, understand their validity and accuracy and then use them to
improve critical metrics, such as those needed for early reperfusion.
4. Heart Failure
4.1. Prevalence of Heart Failure in the Community (Known vs. Unknown)
Currently, around 64.3 million people suffer from heart failure worldwide, with this
number generally increasing [47]. The main reasons behind this are linked to an aging,
global population growth and better survival under contemporary heart failure therapy.
Heart failure prevalence differs depending on geographic region and socio-economic status.
In developed countries, the prevalence of heart failure varies between 0.8% and 4.0% of
the adult population with an increasing incidence with increasing age [48]. This wide
range occurs as a result of the variety of methods used to estimate heart failure prevalence.
Prevalence measures rely on different models and estimations based on the International
Statistical Classification of Diseases and Related Health Problems-codes, patients’ clinical
signs and symptoms, echocardiographic exams and natriuretic peptides, which each have
their own limitations. This is further confounded by the fact that half of heart failure
patients suffer from heart failure with preserved ejection fraction (HFpEF) [49,50].
Due to the methodology used for heart failure prevalence estimations, unrecognized
heart failure patients are not taken into account. Thus, a relevant number of unreported
cases is very likely. Within the population of unrecognized cases, up to 76% are consid-
ered to be patients with HFpEF [49]. The main reasons for the underestimation of heart
failure are the nonspecific symptoms and overlap with other morbidities and the lack of
availability of essential diagnostic tests, such as echocardiography, and the measurement
of natriuretic peptides in primary care medicine. Using interpolations, heart failure preva-
lence, including recognized and unrecognized cases, is estimated to be 4.2% within the
general population [48].
4.2. Utilization of Wearables in Heart Failure
Wearables provide various functional and physiologic data for monitoring heart
failure symptoms and status. These data might be used for the management of heart
failure patients in addition to data acquired during in-patient and out-patient visits, or
by implantable cardiac devices. Wearables offer the opportunity to assess patients’ status
closely outside the classic clinical settings. However, most of these devices are developed as
a wellness or lifestyle feature rather than medical devices with approval by local authorities.
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Approval by the FDA or other local authorities is a prerequisite for integration into patient
clinical management.
Most wearable technologies currently available depend on a connected smartphone
or tablet. However, smartphones are currently used by only 77% of the general population.
In the typical heart failure population >65 years of age, only 53% own a smartphone
(www.statistica.com (accessed on 2 April 2021)). This fact currently limits the use at least of
smartphone-based wearable technologies in the heart failure population. However, even
in this age group, smartphone usage is increasing by 7% per year. Thus, in a few years,
smartphones are expected to be used in >70–80% of the people in this age group.
4.3. Wearables for Detection of Heart Failure in the Community
An additional benefit of the implementation of wearables for the screening of un-
recognized heart failure and support of current heart failure management is conceivable.
Wearables are able to measure and acquire a number of heart failure surrogates. Heart rate,
blood pressure, temperature, body weight changes, step count, posture, activity, lung fluid
and heart failure specific questionaries are a selection of parameters acquired by wearables
being potentially used for heart failure management (Table 2).
Table 2. Surrogates for wearable measurement in heart failure.
HF Parameter Method Device
Thoracic fluid Thorax impedance measurement, remotedielectric sensing, seismocardiography Patch, vest, smart shirt
Activity Pedometers, accelerometers, Patch, wrist band, smartwatch, smart shirt
Blood pressure Sphygmomanometer Smart watch, wristband
Body Weight Body weight measurement Smart socks, scale
NYHA functional
class Questionnaires, applications Smart phone, tablet
QoL Questionnaires, applications Smart phone, tablet
Heart rate, heart
rhythm ECG, PPG
Smart watch, wrist band,
patch, chest band, smart shirt
ECG, electrocardiogram; HF, heart failure; NYHA, New York Heart Association; PPG, photoplethysmography;
QoL, quality of life.
Due to the high estimated number of unreported cases in the general population,
contemporary wearables might help to screen for heart failure in the general population.
Studies on the use of wearables to identify unrecognized heart failure in the community
are currently lacking. In a pilot study, Shah et al. used the PPG and accelerometer data
acquired by a wristband wearable in in-patients for the diagnosis of heart failure [51]. They
demonstrated that the PPG and accelerometer data had a diagnostic accuracy of 74%. If
these data were combined with a selection of patient characteristics, co-morbidities, heart
rate and blood pressure, the accuracy increased to 82% [51]. Studies in the community on
heart failure screening are generally conceivable. Clinical trials on screening for subclinical
AF in the general population have shown that the concept of wearable-based screening
for specific diseases is feasible [52], and could, therefore, be translated into a heart failure
cohort. As heart failure is a clinical diagnosis, the challenge in screening for heart failure
is the identification of asymptomatic individuals. Multiple parameters must be used for
screening and diagnosis. Focusing on a population >65 years of age and screening for risk
factors of heart failure and co-morbidities might identify heart failure patients and guide
further diagnostic evaluation [53,54].
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4.4. Wearables for Ambulatory Heart Failure Management
Patients with heart failure admitted for heart failure decompensation will have another
hospitalization within 30 days in 25% and in 40% of the cases within 12 months after
discharge [55]. Each decompensation and hospital admission is associated with higher
mortality, and furthermore, heart failure hospitalization relevantly burdens the health care
system [56]. Thus, a reduction in heart failure decompensations lowers mortality and
reduces the cost burden on the health care system. Studies using telemedicine monitoring
weight gain or intrathoracic impedance have failed to reduce hospitalizations. Despite some
methodological weaknesses, these studies indicate that the use of these single parameters is
probably not sufficient to monitor heart failure status, although thoracic impedance is able
to detect cardiac decompensation far upstream in the cascade [57–59]. The management
of patients with heart failure using direct pulmonary pressure monitoring (CardioMEMS)
reduces heart failure hospitalization by 27% [60]. However, this technology is invasive
and expensive. In the MULTISENSE trial, heart failure hospitalization could be predicted
with a sensitivity of 70% using a number of parameters provided by implantable cardiac
electronic devices [61]. From these experiences, the management of chronic heart failure
using wearables should ideally use multiple parameters and upstream monitoring of
intracardiac diastolic pressure or tissue water [62,63].
The spectrum of wearable devices includes clothing, such as vests, shirts, socks, and
accessories, such as smartwatches, wristbands, patches, glasses and rings. These biosensors
are able to detect heart failure-specific physiologic parameters. This information can be
supplemented by anamnestic information of the patient.
4.5. Activity in Heart Failure
Several studies have demonstrated that wristband-, smartwatch- or patch-integrated
pedometers or accelerometers are able to provide data on the activity in heart failure
patients [64–68]. The accuracy of the step count differs between different devices and
manufacturers. Walking speed and the side the watch or wristband is worn impact step
count and activity measures [69]. Despite these inaccuracies, step count seems to correlate
with the New York Heart Association (NYHA) functional class. In a study comparing
patients in NYHA class II and III over a period of 2 weeks, patients in NYHA class III
revealed significantly fewer step counts [70].
Activity measured via accelerometers is associated with prognosis. In a Japanese
population, a step count of <4889 steps per day was an independent risk factor with a
hazard ratio of 2.28 [71]. Loprinzi demonstrated in an American population that a 1-h
increase in daily activity lowers the risk of death by 35% [72]. In a small study with 10 pa-
tients admitted for newly diagnosed heart failure, activity measured via daily step count
correlated with left ventricular ejection fraction (LVEF), six-minute walk test (6MWT) and
peak VO2 after hospital discharge (r = 0.44, r = 0.67 and r = 0.57, respectively) [73]. A Czech
study demonstrated a decrease in activity during COVID-19 quarantine in heart failure pa-
tients. In the first 3 weeks of restrictions, daily step count decreased significantly by 16.2%
compared to the period before the beginning of the quarantine [74]. Currently, there is no
standard in the measurement of physical activity. Further trials are in progress to compare
wearable derived data with classic heart failure measures, such as 6MWT, laboratory and
specific heart failure quality of life questionnaires (NCT4191356). A prerequisite for the
implementation of activity measure into heart failure management is standardization and
prospective clinical trials to prove that the activity-guided management of heart failure has
a prognostic impact [75].
4.6. Blood Pressure Control in Heart Failure
Recently, a smartwatch-integrated sphygmomanometer was approved by the FDA
for wearable-based blood pressure measurement. Kuwabara et al. showed only minimal
deviation from manual standard measurements [76]. Wearable-based blood pressure moni-
toring may support the prevention of heart failure, as hypertension is among the dominant
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causes of heart failure. In chronic heart failure, close blood pressure measurements may
allow the optimal titration of heart failure medication to avoid hypotension and increase
therapy adherence.
4.7. Heart Rate and Arrhythmia Management
Most wrist-worn wearables or adhesive patches are able to monitor heart rate either
via PPG or ECG. PPG measurements are especially vulnerable during exercise. At rest
correlation with the standard ECG using different devices was acceptable. However, at
different levels of exercise, the limits of agreement were very poor (−22.5 to 26.0 bpm
up to −41.0 to 36 bpm) [77]. Moayedi et al. confirmed the limitations of the PPG-based
measurement of heart rate in a heart failure population [78]. Due to the vulnerability of
the PPG towards motion heart rate, measurement and monitoring should focus on resting
heart rate, which shows the best correlation with the ECG gold standard.
4.8. Intracardiac Pressures and Tissue Water
Changes in intracardiac pressures and increases in tissue water arise at the beginning
of the cascade of cardiac decompensation well before clinical signs emerge. Thus, moni-
toring of these physiologic parameters is feasible by implantable sensors. Sensor-guided
management has been shown to reduce heart failure hospitalization [60]. Noninvasive
wearables, such as patches, shirts or vests, are able to detect thoracic fluid accumulation
by impedance measurements, remote dielectric sensing (ReDS) or seismocardiography.
Feasibility and observational studies could demonstrate that these emerging technologies
are able to differentiate between compensated and decompensated heart failure status
or even reduce hospitalizations [79,80]. Another method to monitor thoracic fluid is a
radiofrequency sensor included in a patch (µCor, Zoll, Pittsburgh, PA, USA). The technolo-
gies based on a single parameter to detect heart failure decompensation must prove their
clinical value in further clinical trials (NCT03586336 and NCT03476187). In the Link-HF
trial, a multisensor approach, including ECG, accelerometer, temperature and intrathoracic
impedance, was analyzed [68]. After a normalization period, this multisensor patch was
able to show a sensitivity of 76–88% and a specificity of 85% for an alert with a median of
6.5 days before decompensation [68]. The Nanowear wearable Heart Failure Management
System Multiple Sensor Algorithm Development and Validation trial is currently investi-
gating the SimpleSENSE device and whether heart failure hospitalization can be predicted
by this multisensor technology (NCT03719079). The preliminary clinical data on invasive
and noninvasive approaches on thoracic fluid assessment show that the sensitivity of the
wearables is comparable to invasive sensors and cardiovascular implantable electronic
device-based monitoring [61].
The wearable-based management of heart failure might be a promising addition in the
individualized treatment of heart failure. Especially for devices monitoring thoracic fluid or
intracardiac pressures, a standard operating procedure for the management of the patient
is essential, as the patient is still asymptomatic in this early stage of decompensation. For
the implementation of wearable technologies in clinical routine, we need further studies
and evidence with a focus on outcome and cost effectiveness.
5. Wearables to Assist in Transition of Medical Management from the Clinic to
the Home
In recent years, there has been a shift in the direction of de-institutionalization by
moving hospital care towards community-based care due in part to a growing elderly
population with a greater burden of chronic disease and scarcity of hospital beds. The
importance and urgency of this have further been realized with the COVID-19 pandemic,
which has led to cancellations of nonurgent hospital visits and hospitalizations. In general,
there is now an increased acceptance of a telehealth model by both patients and healthcare
providers alike. Nonetheless, among the major challenges of community-based care is
the lack of access to information derived from routine examination and monitoring that
is otherwise afforded by direct patient contact. In this regard, leveraging data via remote
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patient monitoring (RPM) from wearable devices may help overcome this obstacle. In
the real-world setting, teleconsultations instead of outpatient clinic visits have been made
possible by implementing an on-demand app-based heart rate and rhythm monitoring
infrastructure [81–83].
The use of RPM is not a new concept. The benefit of RPM has been demonstrated in
implantable cardiac devices. In fact, the use of RPM in patients with implanted devices
(pacemakers, ICDs and cardiac resynchronization therapies) has been shown to be associ-
ated with a reduction in mortality, depending on the level of adherence [84,85]. The findings
from these studies were confirmed in a meta-analysis of nine randomized controlled tri-
als which also found reduced odds of inappropriate shock with the implementation of
RPM [86]. However, there are limited data on the use of wearables in this setting.
Modern wearables are equipped with sensors that are able to monitor physiological
parameters, such as temperature, heart rate, HRV, respiratory rate, arterial oxygen satura-
tion, thoracic fluid content and blood pressure. It has been suggested that these wearables
may be comparable to implanted devices for the detection of impending heart failure
rehospitalization [68]. In such patients, the early detection and institution of treatment
may prevent subsequent deterioration. Furthermore, it may have a role in patients with
viral-like infections and reduce the spread of outbreaks [87]. A study using retrospective
data from the Fitbit wearable found that it could be used to predict influenza-like illness
at an individual- and population-level [88]. It has also been tested in patients with the
COVID-19 infection, where physiological data derived from this device have been shown
to relate to the severity of illness on specific days [89].
The potential benefits of wearables in community-based care include an improvement
in patient outcomes and quality of life, reduced anxiety levels in patients with chronic
diseases who are monitored continuously, reduced hospital admissions and visits and
decreased length of hospital stays (Figure 4). Furthermore, it facilitates a patient-centered
care model with better patient–physician collaboration.
Figure 4. Implementation of wearables may facilitate the transition from hospital-based to home care
(created with BioRender.com, accessed on 2 April 2021).
Nevertheless, with the increased adoption of RPM, there needs to be greater data
transparency, better protocols for the safe implementation of RPM and more user-friendly
systems [90]. Further hardware refinements are also needed to address some of the current
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challenges faced with the use of wearables for RPM that relate to long-term application
(e.g., patches), skin-device interface and energy autonomy [91].
6. Wearables for Return to Play in Patients with Congenital and Acquired
Cardiovascular Disease
Cardiac deconditioning is often a lifelong issue in children and young adults with
congenital heart disease, inherited arrhythmias and cardiomyopathies. These patients often
do not have the opportunity, inclination or education to participate in safe and effective ex-
ercise, and historically, their physicians and parents have further limited their participation
and fostered a fear of sports. This affects their cardiopulmonary health, and has psychoso-
cial consequences, especially when a lack of participation in peer activities or sports leads to
isolation and further sedentary behaviors [92]. The past decade has witnessed a paradigm
shift in sports allowances in patients with congenital heart disease [93], arrhythmias [94,95],
cardiomyopathies [96–98] and even ICDs [99,100]. Can direct-to-consumer monitors assist
in the present trajectory of increased participation in sports in a population of children,
adolescents and young adults with congenital and acquired heart disease, arrhythmia
syndromes and cardiomyopathies?
These devices are part of the evolution from episodic to continuous patient care in
adult cardiac disease. There are numerous pediatric cardiac conditions that might be better
managed with this technology [101]. However, most mobile health technologies, especially
wearable biosensors, are not designed for children. As in adults, there are several aspects
of disease in this younger population that should be considered of interest: heart rate
monitoring, arrhythmia detection, blood pressure monitoring and supporting exercise
and rehabilitation. Unlike adults, AF will rarely be the suspected arrhythmia. “Normal”
heart rate and blood pressure are age- and occasionally disease-dependent, and even the
duration and depth of exercise is age- and disease-dependent.
Children and adolescents with congenital heart disease, inherited arrhythmias and
cardiomyopathies often spent a lifetime under the “medical microscope”, with frequent
physician visits, procedures, hospitalizations and concerned parental scrutiny. Device
design must allow pediatric and adolescent patients to act and feel like kids and teens, not
like patients under further surveillance [101]. Parents and children with chronic illnesses
often show signs of increased stress, so wearability should not worsen this and should
target improved quality of life. It is interesting to note that the use of insulin pumps reduces
both patient and caregiver anxiety, in part because of decreased fear of hypoglycemia [102].
Validated wearables should aim to do the same for high-risk congenital and acquired heart
disease, cardiomyopathy and inherited arrhythmia populations.
This is a population where hospitalizations, surgeries, medications and procedures
are expected and where cardiac rehabilitation, heart rate and rhythm monitoring, response
to medications and return to play can be supported by validated wearables. For exam-
ple, continuous monitors might be useful to up titrate or assess the heart rate, blood
pressure and arrhythmia response to beta blocker therapy. Data will provide continuous
assessment versus a single snapshot provide by an in-person clinic assessment, ECG and
exercise testing.
Children and adolescents with inherited arrhythmia syndromes or channelopathies
represent a unique population where this technology has the potential for a number of
applications. This is a group of conditions where sports allowances vary but are becoming
more permissive, sometimes in contrast to guideline recommendations. The LQTS is the
most common channelopathy and the one for which we have the most data about risk and
sports participation. Exercise has been associated with arrhythmic events in LQTS patients,
especially those with type 1 LQTS [103]. However, many LQTS patients exercise despite the
restrictions, and recent data suggest that LQTS subjects who receive appropriate disease-
specific therapy can participate in sports safely [94] Current guidelines are more permissive
in this population [95]. As the guidelines and cardiologists become more liberal in their
approach to sports in this population, patient-friendly monitors could provide a measure of
reassurance as this population, previously restricted, engages in sports. Wearable monitors
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can be used to follow the QT interval at baseline, with the addition of medications, at rest
and with activity in patients with LQTS [40]. This could help assess for arrhythmias and
worsening of repolarization with more profound QT prolongation or the appearance of T
wave alternans that might predict arrhythmias.
Hypertrophic cardiomyopathy (HCM), the most commonly inherited cardiomyopathy,
has been linked to sudden death during exercise [104]. Traditionally, this has been a
population with significant sports restrictions. However, there is a move to liberalize
restrictions as researchers and cardiologists challenge the widely held view that HCM is
the most common cause of sudden cardiac death in young patients who participate in
vigorous activities [96]. There is a prospective observational study (Lifestyle and Exercise
in HCM) enrolling HCM patients across a range of activity levels comparing outcomes in
those participating in high levels of activity with more sedentary individuals. Data from
wearables will likely prove to be of great utility in this population as we find a balance
between sports and safety and finally allow this population the physical and psychological
benefits of an active lifestyle.
Acquired heart disease in children and adolescents is far less common than in adults.
Acquired heart diseases in this young population where a safe return to sports must be
considered include Kawasaki disease, rheumatic carditis and viral myocarditis. The re-
cent COVID-19 pandemic has resulted in two new potential acquired cardiac diseases in
young people: myocarditis as a result of the acute infection and heart failure/myocarditis
as a consequence of the multisystem inflammatory syndrome in children [105]. Signifi-
cant cardiac morbidity has been observed among hospitalized COVID-19 adult patients
occurring in 22%, higher than the 1% in non-COVID-19 acute viral infections [106,107].
Myocarditis from myocyte invasion by the virus can result in dysfunction, arrhythmias and
death. Return to play is predicated on the normalization of ventricular function, absence of
biomarkers of inflammation and necrosis and absence of arrhythmias [107]. Risk assess-
ment after recovery at present is based on extensive cardiac testing with echocardiograms,
stress testing and rhythm monitoring. Wearable monitors in this scenario will enable the
continual assessment of unlimited duration, not a single snapshot in time. The editorials
on this topic acknowledge the many uncertainties about this disease and its recovery [107].
Successfully integrating continuous monitoring into cardiovascular care as patients
increase sports engagement and return to sports after an event or illness will require
collaboration between clinicians, industry and regulatory bodies. Small children will be
uniquely challenging with size, physiologic and compliance considerations, but teens and
young adults will be an “easy sell” with their technological sophistication and openness
to adopting and using new technologies. The challenges that exist can and will be solved.
This new technology is poised to extend the physician’s ability to safely care for young
patients, some who are adopting a more active lifestyle and others reengaging in sports
after an illness.
7. Sleep Apnea
Sleep-disordered breathing is common in the community, and the prevalence is
increasing. Current estimates report that the prevalence of moderate-to-severe sleep-
disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) is 10%
among 30–49-year-old men, 17% among 50–70-year-old men, 3% among 30–49-year-old
women and 9% among 50–70 year-old women, all with relative increases of 14–55% over
the past 2 decades [108]. Sleep apnea, through multiple mechanistic pathways, is associated
with an increased risk of hypertension, arrhythmias, stroke, heart failure and cardiovascular
disease [109].
Screening for sleep apnea is typically through continuous nocturnal oximetry, and
multiple oximetry tools are available by prescription and direct-to-consumer. However,
although oximetry is used for sleep apnea screening, polysomnography remains the gold
standard for the diagnosis. A study using a wrist-worn reflective photoplethysmography
was compared to polysomnography in 188 recordings with a favorable correlation (correla-
Sensors 2021, 21, 2539 16 of 25
tion = 0.61; estimation error = 3 ± 10 events/h) [110]. The estimated apnea–hypopnea index
correlation was also favorable compared to polysomnography across different severities of
obstructive sleep apnea (ROC–AUC: mild: 0.84; moderate: 0.86; severe 0.85). As noted by
the authors of this study, the wrist-worn tool diagnostics can be implemented in wearables,
such as smartwatches.
Other applications of electrogram monitoring may also be relevant to the diagnosis of
sleep apnea, in isolation or combination with photoplethysmography, as the disorder is
often characterized by paroxysms of nocturnal bradycardia and conduction delay as well
as intermittent tachyarrhythmias. Sleep apnea can also impact the neuromodulation of
the heart, which influences HRV [111]. Using HRV in 30 patients with sleep apnea, the
RR interval correlated with the apnea hypopnea index (r = 0.663, p = 0.003). Using the RR
interval alone, 25 of the patients would have been diagnosed with obstructive sleep apnea.
8. Artificial Intelligence
Among the most straightforward applications of AI to wearable devices is the auto-
matic interpretation of ECG signals and the classification of arrhythmias from wearable
devices [112]. For example, AliveCor obtained FDA approval for a suite of AI algorithms
to detect not only AF but also sinus rhythm with premature ventricular contractions,
supraventricular ectopy and sinus rhythm with wide QRS [113]. Such AI algorithms could
alleviate the clinicians’ burden in manually interpreting the increasing number of ECGs
obtained from wearable devices and only generate alerts when a clinical action is needed.
AI applied to ECGs could also help identify other cardiac conditions beyond ar-
rhythmias. Many cardiovascular diseases, such as left ventricular systolic dysfunction
(LVSD) and HCM, are underdiagnosed, because the diagnostic tests are too costly to
perform in a broad asymptomatic population. In the past, statistical models were devel-
oped based on discrete ECG features, such as left bundle branch block and ST-T segment
changes [114–116]. However, such models were based on clinicians’ identification of these
features, thereby requiring manual ECG interpretation. Additionally, traditional statistical
models, e.g., logistic regression models based on a few ECG features, had poor performance,
resulting in limited clinical utility.
In recent years, a number of ECG-based AI algorithms have shown great performance
in detecting cardiac conditions, such as LVSD [117,118], HCM [119] and MI [120]. The
performance of these AI algorithms is typically better than risk scores currently used
in routine practice, e.g., the CHA2DS2-VASc score. For example, one ECG-based deep
learning algorithm showed a c statistic of 0.93 for identifying low ejection fraction [117,118],
and another algorithm identified HCM with a c statistic of 0.96 [119].
When assessed in a pragmatic randomized controlled trial, the AI ECG algorithm,
serving as a clinical decision support tool, significantly improved the diagnosis of low
EF in 22,641 patients managed in routine primary care settings [121,122]. Therefore, the
AI tool could identify asymptomatic LVSD at the early stage, so the treatment can be
initiated to prevent HF progression and mortality [123,124] When applied in the emergency
department, the ECG-based AI algorithm outperformed NT-proBNP for identifying pa-
tients with LVSD, which could serve as a quick, inexpensive approach to guide subsequent
echocardiography decisions in acute settings [125].
As an increasing number of consumer-grade wearables are equipped with the capacity
to record ECGs, the ECG-based AI algorithms can help screen broad populations for rare
conditions, such as HCM, asymptomatic LV dysfunction or occult arrhythmias. The ability
to detect MI and LVSD could also alert patients to seek medical care early and inform
diagnostic approaches when patients arrive in the hospital. However, a major challenge is
that most of the AI algorithms have been trained based on using signals from conventional
12-lead ECGs. As such, the algorithm performance when using single-lead ECGs is variable,
and the algorithms may require retraining or tuning before they can be readily applied to
ECGs obtained from wearable devices.
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ECG-based algorithms can also play a role in chronic disease management, such as hy-
pertension and diabetes [126,127]. For example, an AI algorithm was developed based on
raw ECG signals recorded by a commercial wearable device (Medtronic Zephyr BioPatch™
HP80) and has been shown to predict hypoglycemic events [127]. Although commercial de-
vices are available for patients to monitor HbA1c at home, blood glucose testing requires a
drop of blood from a finger prick and does not allow continuous monitoring, so continuous
monitoring using AI-enhanced wearable devices is an attractive alternative.
The data collected from wearable devices could also help augment existing prediction
models. Most prediction models are developed using data collected from clinical settings
and lack information, such as lifestyle factors, sleep patterns and daily activities, which are
known risk factors for cardiovascular diseases and mortality [128,129]. Traditionally, such
data are collected based on self-reporting, and are thereby subject to recall bias. Recently, a
number of studies assessed the relationship between health outcomes and data collected
from wearable devices, such as step count, sleep duration and sleep variability [130–132].
For example, one study found that a higher step count on postoperative day one was
associated with significantly lower odds of prolonged length of stay in patients undergoing
major surgery [131]. Therefore, AI models could be more powerful when data from
wearable devices are integrated with clinical data in the electronic health record.
Historically, the derivation and application of machine learning algorithms have
typically been computationally expensive and performed by supercomputers or high-end
workstations. Recently, cloud services, such as Amazon AWS or Google Cloud, have
been increasingly used for data storage and maintenance, given the reduction in cost and
maintenance as well as the elasticity that cloud architectures provide [133]. Previous studies
have demonstrated the utility of high-performance cloud computing resources, directly
integrated into the EHR, for developing and deploying advanced predictive models [134].
Therefore, AI could be embedded into EHR, leveraging medical history as well as real-
time data transmitted from the wearable devices, to generate clinically actionable alerts.
However, future studies are needed to prove this concept. Additionally, some “lean”/less
computationally demanding ML algorithms, particularly those that are applied to shorter
times series data, can be applied directly on wearable devices without the must move data
to a cloud service.
The real-world effectiveness and clinical impact of AI applied to wearable devices also
depends on clinicians’ and patients’ uptake. Although many clinicians are interested in
new technologies, others may be skeptical. AI is often considered a “black-box” technology,
making it difficult for some clinicians to trust the results or communicate the meaning
of AI-derived findings to patients [135,136]. Moreover, a recent study of abnormal pulse
detected by the Apple Watch found that nearly 90% of the alerts did not lead to clinically
actionable diagnoses, leading to concerns of increased low-value health utilization [137].
A recent study of patients’ views of wearable devices and AI found that only half of
patients feel that the digital tools and AI constitute an important opportunity, and 11%
considered them a danger [138] Some patients fear that the misuse of technology could
threaten the humanistic aspect of health care, which is a valid concern, since the use of
wearable devices is often outside the health system without any interaction with their
clinicians. This could contribute to the high dropout and incomplete follow up of some
large-scale implementations of digital monitoring programs and highlight the need for
patient engagement and education [139,140].
In summary, AI applied to wearable devices could enable the automatic classification
of arrhythmias, early detection of other cardiac conditions, improved management of
chronic diseases and augmented performance of existing prediction models. However,
there are a number of challenges, ranging from the transportability of the algorithms,
and the integration of data from wearable devices with clinical data, to the adoption by
clinicians and patients. How to maximize the potential of AI and wearable devices without
significantly increasing health utilization and burden on clinicians and patients remains to
be further investigated.
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9. Future Perspectives
Mobile technologies are growing rapidly and will be ubiquitous in the near future.
Supporting evidence of the benefit for users, patients or doctors is crucial for future use
in clinical practice. Unselected measurements of singular surrogates without predefined
decision pathways have not turned out to be successful, despite promising concepts [58].
Appropriate clinical pathways, therefore, must be developed and evaluated measuring
various parameters or surrogates using wearables in order to provide a benefit in different
clinical scenarios or patient cohorts. This also includes appropriate training for users,
patients and prescribing physicians.
One concern among doctors when using wearables and new technologies is data
overload [141]. With the expected amount of data, AI can help with the selection and
presorting and make the evaluation more efficient. AI can also unlock completely new and
previously unused data. The measurement of vocal biomarkers shows a good correlation
with the degree of pulmonary hypertension [142]. In patients with heart failure, vocal
biomarkers correlate with heart failure hospitalizations and mortality [143]. In a proof-of-
concept study, AI was able to ensure the contactless detection of cardiovascular arrests
using smart speakers or smartphones and differentiate between agonal breathing and
hypopnea, central apnea and obstructive apnea [144].
These early results are suggestive of a future role for vocal biomarkers in remote
monitoring and remote patient management.
Since the COVID-19 pandemic, the acceptance and implementation of mobile tech-
nologies was catalyzed in the field of cardiac electrophysiology, as it was in every field of
medicine [145]. The experience of the TeleCheck-AF project shows that a fast, efficient and
powerful implementation of new clinical workflows using mHealth is feasible [83]. The
integration of wearable technologies in other subspecialties of cardiology should take into
account the different perspectives of all players in this field, namely, the user or patient
and the treating physician, but also the legislation, insurance and provider.
10. Conclusions
Advances in wearable technologies have provided new opportunities for the diagnosis
and management of cardiovascular diseases and their risk factors. The possibilities and
implementation of wearable cardiac monitoring beyond AF are increasing continuously.
The management of nonatrial fibrillation arrhythmias represents a broad field of wearable
technologies in cardiology. Implementation in other patient cohorts, such as STEMI, heart
failure or sleep apnea, is feasible and expanding. Medical devices that are marketed directly
to consumers, in addition to current and future physician-ordered testing devices, will
augment our current reach and effort in the management to help address the increasing
worldwide burden of cardiovascular diseases. In addition to appropriate accuracy, clinical
studies must address the validation of clinical pathways, including the appropriate device
and the clinical decisions resulting from the surrogate assessed. These tools must lead to
actionable approaches to reduce cardiovascular disease risk factors or augment the use
of guideline-based therapies. As each technology is considered, its use must be weighed
against the impact of the demand on the healthcare system for the incorporation and inter-
pretation of the diagnostic data, the value of downstream diagnostics and therapies that
will naturally increase with broader screening, and the personal consumers of these tech-
nologies as they are drawn into a more dynamic relationship with their health, physiology
and healthcare providers.
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